Journal
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
Volume 26, Issue 1, Pages 35-45Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2012.01.001
Keywords
Hepatic regenerative medicine; Cellular therapy; Embryonic hepatocytes; Hepatic stem/progenitor cells; Induced pluripotent stem cells; Bone marrow-derived stem cells
Categories
Funding
- University of Padova
- Regione Piemonte
- Fondazione CRT (Torino, Italy)
Ask authors/readers for more resources
Orthotopic liver transplantation (OLT) represents the only reliable therapeutic approach for acute liver failure (ALF), liver failure associated to end-stage chronic liver diseases (CLD) and non-metastatic liver cancer. The clinical impact of liver failure is relevant because of the still high ALF mortality and the increasing worldwide prevalence of cirrhosis that, in turn, is the main predisposing cause for hepatocellular carcinoma (HCC). Moreover, in the next decade because an increased number of patients reaching end-stage disease and requiring OLT may face a shortage of donor livers. This clinical scenario led several laboratories to explore the feasibility and efficiency of alternative approaches, involving cellular therapy, to counteract liver failure. The present chapter overviews results and concepts emerged from recent experimental and clinical studies in which adult or embryonic hepatocytes, hepatic stem/progenitor cells, induced pluripotent stem (iPS) cells as well as extrahepatic stem cells have been used as putative transplantable cell sources. (c) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available